ENDOMETRİOİD ENDOMETRİAL KARSİNOMDA KLİNİKOPATOLOJİK ÖZELLİKLER İLE DNA UYUMSUZLUK ONARIMI PROTEİNLERİ VE P53 DURUMU ARASINDAKİ İLİŞKİ

Year 2025, Volume: 88 Issue: 4, 249 - 255, 30.10.2025

Aysel Bayram , Sidar Bağbudar , Asiye Üzümcü , Atahan Toyran , Semen Önder

https://doi.org/10.26650/IUITFD.1720155

Abstract

Amaç: Bu çalışmanın amacı, endometrioid endometrial karsinomda (EEK), geleneksel olarak prognostik klinikopatolojik özellikler ile immünohistokimyasal olarak değerlendirilen DNA Uyumsuzluk Onarımı (DUO) proteinleri ve p53 ekspresyonunun durumu arasındaki ilişkiyi değerlendirmektir. Material and Methods: A total of 142 EEC patients who underwent hysterectomy and lymph node resection between 2018 and 2024 were included. Immunohistochemical analysis was performed for MLH1, MSH2, MSH6, PMS2, and p53. Results: Our study showed that 66.2% of cases were MMR profi cient and 33.8% were MMR deficient (dMMR). dMMR cases were significantly associated with higher International Federation of Gynecology and Obstetric (FIGO) Grade 3 tumours (33.3% vs. 10.6%) and cervical stromal invasion (39.6% vs. 23.4%). However, no signif icant association was found between dMMR and other parameters such as tumour size or lymphovascular invasion. For p53, 11.3% of cases showed mutationtype staining, whereas 88.7% showed the wildtype. p53 mutationtype staining demonstrated significant associations with multiple aggressive clinicopathological features, such as age, FIGO grade, tumour size, myometrial invasion depth, lymphovascular invasion, and cervical stromal invasion. No case exhibited both p53 mutationtype staining and loss of MMR pro teins.

Gereç ve Yöntemler: 20182024 yılları arasında histerektomi ve lenf nodu rezeksiyonu geçiren toplam 142 EEK hastası çalışmaya dahil edildi. MLH1, MSH2, MSH6, PMS2 ve p53 için immünohistokimyasal analiz yapıldı.

Bulgular: Çalışmamız, vakaların %66,2'sinin DUOyeterli ve %33,8'inin DUOyetersiz (DUOy) olduğunu gösterdi. DUOy vakalar, Uluslararası Jinekoloji ve Obstetrik Federasyonu (UJOF) Grade 3 tümörler (%33,3'e karşı %10,6) ve servikal stromal invazyon varlığı (%39,6'ya karşı %23,4) ile önemli ölçüde ilişkiliydi. Ancak, DUOy ile tümör boyutu veya lenfovasküler invazyon gibi diğer parametreler arasında önemli bir ilişki bulunmadı. p53 immünhistokimyasal incelemesinde, vakaların %11,3'ü mutasyon tipi boyama gösterirken, %88,7'si olağan tip boyanma gösterdi. p53 mutasyon tipi boyama, yaş, UJOF derecesi, tümör boyutu, miyometriyal invazyon derinliği, lenfovasküler invazyon ve servikal stromal invazyon dahil olmak üzere birden fazla agresif klinikopatolojik özellik ile anlamlı ilişki gösterdi. Vakaların hiçbirinde eş zamanlı p53 mutasyon tipi boyama ve DUO proteinlerinin kaybı görülmedi.

Sonuç: EEK'lerdeki MMR durumu ve p53 ekspresyonu, tümör UJOF derecesi ve servikal stromal invazyon gibi önemli klinikopatolojik özellikler ile belirgin şekilde ilişkilidir. p53 mutasyon tipi boyanmanın daha geniş bir agresif faktör yelpazesiyle ilişkisi, prognostik değerlendirme ve tedavi stratejileri için EEK heterojenliğini anlamada moleküler sınıflandırmanın önemini vurgulamaktadır.

Keywords

Endometrioid karsinom , MSI , P53 , endometrium karsinomu

ASSOCIATION OF CLINICOPATHOLOGIC CHARACTERISTICS WITH MISMATCH REPAIR PROTEINS AND P53 IMMUNOHISTOCHEMISTRY FINDINGS IN ENDOMETRIOID ENDOMETRIAL CARCINOMA

Abstract

Objective: This study aimed to evaluate the relationship between traditional prognostic clinicopathological features and the status of immunohistochemically assessed mismatch repair (MMR) pro teins and p53 expression in endometrioid endometrial carcinoma (EEC).

Material and Methods: A total of 142 EEC patients who underwent hysterectomy and lymph node resection between 2018 and 2024 were included. Immunohistochemical analysis was performed for MLH1, MSH2, MSH6, PMS2, and p53.

Results: Our study showed that 66.2% of cases were MMR profi cient and 33.8% were MMR deficient (dMMR). dMMR cases were significantly associated with higher International Federation of Gynecology and Obstetric (FIGO) Grade 3 tumours (33.3% vs. 10.6%) and cervical stromal invasion (39.6% vs. 23.4%). However, no signif icant association was found between dMMR and other parameters such as tumour size or lymphovascular invasion. For p53, 11.3% of cases showed mutationtype staining, whereas 88.7% showed the wildtype. p53 mutationtype staining demonstrated significant associations with multiple aggressive clinicopathological features, such as age, FIGO grade, tumour size, myometrial invasion depth, lymphovascular invasion, and cervical stromal invasion. No case exhibited both p53 mutationtype staining and loss of MMR pro teins.

Conclusion: MMR status and p53 expression in EECs are distinctly associated with key clinicopathological features, such as tumour FIGO grade and cervical stromal invasion. The association of the p53 mutation type with a broader range of aggressive factors underscores the importance of molecular classification in under standing EEC heterogeneity for prognostic evaluation and treat ment strategies.

Keywords

Endometrioid carcinoma , MSI , P53 , endometrial carcinoma

References

• Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73. google scholar
• Stelloo E, Nout RA, Osse EM, Jürgenliemk-Schulz IJ, Jobsen JJ, Lutgens LC, et al. Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analYsis of the PORTEC cohorts. Clin Cancer Res 2016;22(l6):4215-24. google scholar
• Vermij L, Smit V, Nout R, Bosse T. Incorporation of molecular characteristics into endometrial cancer Management. HistopathologY 2020;76(l):52-63. google scholar
• Le on-Castillo A, de Boer SM, Powell ME, Mileshkin LR, MackaY HJ, Leary A, et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapY. J Clin Oncol 2020;38(29):3388-97. google scholar
• Imboden S, Nastic D, Ghaderi M, RYdberg F, Rau TT, Mueller MD, et al. PhenotYpe of POLEmutated endometrial cancer. PLoS One 2019;14(3):e0214318. google scholar
• Bakhsh S, Kinloch M, Hoang LN, Soslow RA, Köbel M, Lee CH, et al. Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapY. HistopathologY 2016;68(6):916-24. google scholar
• McAlpine JN, Chiu DS, Nout RA, Church DN, Schmidt P, Lam S, et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer 2021;127(l4):2409-22. google scholar
• van den Heerik ASVM, Horeweg N, Nout RA, Lutgens LCHW, van der Steen-Banasik EM, Westerveld GH, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020;30(l2):2002-7. google scholar
• McAlpine JN, Chai-Zung KH, Kinloch M, Barkati M, Ferguson SE, Fyles AW, et al. CCTG EN10: a phase II study of tailored adjuvant therapy in POLE-mutated and p53- wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER. J Clin Oncol 2023;4l(l6):TPS5632-TPS5632. google scholar
• Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, et al. Molecular subtYpe not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res 2019;25(8):2537-48. google scholar
• Santin AD, Bellone S, Buza N, Choi J, Schwartz PE, Schlessinger J, et al. Regression of ehemotherapy-resistant polymerase e (POLE) ultra-mutated and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin Cancer Res 2016;22(23):5682-7. google scholar
• Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e-mutated and mierosatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol 2015;l(9):1319-23. google scholar
• Mirza MR, Chase DM, Slomovitz BM, dePont Christensen R, Novâk Z, Black D, et al. Dostarlimab for primarY advanced or recurrent endometrial cancer. N Engl J Med 2023;388(23):2145-58. google scholar
• Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, et al. Pembrolizumab plus chemotherapY in advanced endometrial cancer. N Engl J Med 2023;388(23):2159-70. google scholar
• Jamieson A, Huvila J, Leung S, Chiu D, Thompson EF, Lum A, et al. Molecular subtYpe stratified outcomes according to adjuvant therapY in endometrial cancer. Gynecol Oncol 2023;170:282-9. google scholar
• McConechy MK, Talhouk A, Li-Chang HH, Leung S, Huntsman DG, Gilks CB, et al. Detection of DNA mismatch repair (MMR) deficiencies bY immunohistochemistrY can effectivelY diagnose the microsatellite instabilitY (MSI) phenotype in endometrial carcinomas. Gynecol Oncol 2015;137(2):306-10. google scholar
• de Jong RA, Boerma A, Boezen HM, Mourits MJ, Hollema H, Nijman HW. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer 2012;13l(8):1828-36. google scholar
• Shikama A, Minaguchi T, Matsumoto K, Akiyama-Abe A, Nakamura Y, Michikami H, et al. Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas. Gynecol Oncol 2016;140(2):226-33. google scholar
• Talhouk A, Hoang LN, McConechY MK, NakonechnY Q, Leo J, Cheng A, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highlY concordant with final hYsterectomY: earlier prognostic information to guide treatment. Gynecol Oncol 2016;143(l):46-53. google scholar
• Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol 2018;29(5):1180-8. google scholar
• Jumaah AS, Al-Haddad HS, Salem MM, McAllister KA, Yasseen AA. Mismatch repair deficiency and clinicopathological characteristics in endometrial carcinoma: a systematic review and meta-analysis. J Pathol Transl Med 2021;55(3):202-11. google scholar
• Kim SR, Pina A, Albert A, McAlpine J, Wolber R, Blake Gilks C, et al. Does MMR status in endometrial cancer influence response to adjuvant therapy? Gynecol Oncol 2018;15l(l):76-81. google scholar
• Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res 2016;2(4):247-258. google scholar
• Bosse T, Nout RA, McAlpine JN, McConechy MK, Britton H, Hussein YR, et al. Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups. Am J Surg Pathol 2018;42(5):561-8. google scholar
• Okoye EI, Bruegl AS, Fellman B, Luthra R, Broaddus RR. Defective DNA mismatch repair influences expression of endometrial carcinoma biomarkers. Int J Gynecol Pathol 2016;35(l):8-15. google scholar
• Raffone A, Travaglino A, Mascolo M, Carbone L, Guida M, Insabato L, et al. TCGA molecular groups of endometrial cancer: Pooled data about prognosis. Gynecol Oncol 2019;155(2):374-83. google scholar
• Szatkowski W, Nowak-Jastrzşb M, Kluz T, Kmiec A, Cieslak-Stec M, Sliwinska M, et al. Clinicopathological Features and Risk Stratification of Multiple-Classifier Endometrial Cancers: A Multicenter Study from Poland. Cancers (Basel) 2025;17(15):2483. google scholar